In a JAMA Network Open survey study of 3,615 adults, GLP-1 use was 20.5% with a cancer history versus 26.5% without, about 30% lower odds.
Recap by typeshit. Full story at The Cardiology Advisor.
Researchers found the peptide they built as a treatment already circulates in human blood, at lower levels in people with cognitive impairment.
Topol points to work suggesting the body's own GLP-1 family peptides help reduce inflammation in the gut. Details are thin, so tap through for the study.
Medscape explores whether GLP-1 medicines might help keep people with schizophrenia out of the hospital. Tap through for the evidence behind the idea.
The weight loss drug class started with a lizard. A short local feature looks at how the Gila monster led researchers to GLP-1 medicines.
The obesity medicine specialist told a Fall Clinical 2026 panel that sleep apnea, MASH and heart coverage can open GLP-1 access, and that retatrutide could reach market next year.
In a 12-week study of 245 adults, Omada reports its members cut body fat percentage about twice as much as usual care. Results go to WOC 2026 in Boston.
Loading…